Application of anti-Scl 70 antibody and anti-centromere antibody in systemic sclerosis
Objective:To investigate the correlation of serum levels of anti-topoisomerase Ⅰ antibody(anti-Scl70 antibody)and anti-centromere antibody(AC A)with the clinical characteristics of systemic sclerosis(SSc).Methods:A total of 84 pa-tients,diagnosed with SSc in Qinghai Provincial Hospital of Traditional Chinese Medicine from January 2011 to December 2021,were selected and grouped according to anti-Sc170 antibody and ACA positivity.The positive distribution of ANA high titer(≥ 1:320)was compared between the anti-Scl70 antibody-negative group and the anti-Scl70 antibody-positive group.Labo-ratory indicators,clinical manifestations,organ involvement,and clinical treatment effect of SSc patients in all groups were e-valuated.Results:In the anti-Scl70 antibody positive group,the positive rate,high-density lipoprotein(HDL),C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),WBC,immunoglobulin A(IgA),IgE,carbohydrate antigen 199(CA199)and pulmonary fibrosis lesions in the positive group were higher than those in the negative group,but the incidence and course of pulmonary hypertension were lower than those in the negative group(P＜0.05).The incidence of digital sclerosis,pulmonary hypertension,and disease course in the ACA-positive group were higher than those in the negative group,but the incidence of pulmonary fibrosis was lower than that in the negative group(P＜0.05).Conclusion:Serum levels of anti-Scl70 antibody and ACA have great value in the diagnosis,treatment and prognosis of SSc patients.
NETL
NSTL
万方数据
